321 related articles for article (PubMed ID: 19858389)
1. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
McDermott U; Settleman J
J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
[TBL] [Abstract][Full Text] [Related]
2. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
3. Somatic pharmacogenomics in cancer.
Ikediobi ON
Pharmacogenomics J; 2008 Oct; 8(5):305-14. PubMed ID: 18679398
[TBL] [Abstract][Full Text] [Related]
4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
5. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
6. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
Hirsch FR
Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer.
Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M
Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954
[TBL] [Abstract][Full Text] [Related]
8. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
11. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
12. EGFR FISH versus mutation: different tests, different end-points.
Cappuzzo F
Lung Cancer; 2008 May; 60(2):160-5. PubMed ID: 18367287
[TBL] [Abstract][Full Text] [Related]
13. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
14. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S36-41. PubMed ID: 19393834
[TBL] [Abstract][Full Text] [Related]
15. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
16. Targeting protein kinases in cancer therapy: a success?
Pearson MA; Fabbro D
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1113-24. PubMed ID: 15606337
[TBL] [Abstract][Full Text] [Related]
17. [Genomic markers and anticancer chemotherapy].
Nishiyama M
Gan To Kagaku Ryoho; 2008 Feb; 35(2):194-9. PubMed ID: 18281756
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to tyrosine kinase inhibitors during cancer therapy.
Engelman JA; Settleman J
Curr Opin Genet Dev; 2008 Feb; 18(1):73-9. PubMed ID: 18325754
[TBL] [Abstract][Full Text] [Related]
19. Personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
[TBL] [Abstract][Full Text] [Related]
20. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]